Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 100
- Registration Number
- NCT00002423
- Locations
- 🇺🇸
IDC Research Initiative, Altamonte Springs, Florida, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Kansas City AIDS Research Consortium, Kansas City, Missouri, United States
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002391
- Locations
- 🇺🇸
Children's Hosp Los Angeles, Los Angeles, California, United States
🇺🇸Children's Diagnostic Treatment Ctr, Fort Lauderdale, Florida, United States
🇺🇸UMDNJ / Division of Allergy Immunology & Infectious Diseases, Newark, New Jersey, United States
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 440
- Registration Number
- NCT00017719
- Locations
- 🇺🇸
Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States
🇺🇸WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States
🇺🇸Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States
A Phase I Study of Methotrexate for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 30
- Registration Number
- NCT00000834
- Locations
- 🇺🇸
Cedars Sinai Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Kansas School of Medicine, Wichita, Kansas, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 217
- Registration Number
- NCT00000902
- Locations
- 🇺🇸
Connecticut Children's Med Ctr, Farmington, Connecticut, United States
🇺🇸Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 240
- Registration Number
- NCT00014937
- Locations
- 🇮🇹
Spedali Civili - Carosi, Brescia, Italy
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 240
- Registration Number
- NCT00001083
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Univ of Miami (Pediatric), Miami, Florida, United States
🇺🇸North Shore Univ Hosp, Great Neck, New York, United States
A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 6
- Registration Number
- NCT00001108
- Locations
- 🇺🇸
Cook County Hosp, Chicago, Illinois, United States
🇺🇸Univ of Massachusetts Med School, Worcester, Massachusetts, United States
🇺🇸Univ of Mississippi Med Ctr, Jackson, Mississippi, United States
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
- Conditions
- Locations
- 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 730
- Registration Number
- NCT00005918
- Locations
- 🇺🇸
The CORE Ctr, Chicago, Illinois, United States
🇺🇸Univ of Texas Med Branch, Galveston, Texas, United States
Tan tock Seng Hosp
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.